A photo of Rebecca Marsh.

Rebecca A. Marsh, MD

  • Clinical Director, Primary Immune Deficiency Program
  • Co-Director, Diagnostic Immunology Laboratories
  • Clinical Director, HLH Center of Excellence
  • Professor, UC Department of Pediatrics
Each patient and family is different, and I enjoy getting to know each person and helping them live their best life through optimal treatment of their immune deficiency.



I’ve always been fascinated by the immune system and also felt a calling to pediatrics. I enjoy working with people and developing long-term relationships with patients and families, so my career in primary immune deficiencies and hematopoietic cell transplantation is a perfect fit. My practice combines my love of immunology with caring for pediatric patients and working in a team-based setting.

As an immunologist and transplant physician, I treat patients with primary immune deficiencies and immune regulatory diseases, which are collectively called inborn errors of immunity. I’m the clinical director of the Primary Immune Deficiency Program and co-director of Diagnostic Immunology Laboratory.

Our practice provides a variety of treatments for patients, including allogeneic hematopoietic cell transplantation. Each patient and family is different, and I enjoy getting to know each person and helping them live their best life through optimal treatment of their immune deficiency.

We have a large group of specialists in the diagnosis and treatment of inborn errors of immunity. We also have the largest clinical laboratory specializing in primary immunodeficiency diagnostics. Our physician group consists of several experts in primary immunodeficiencies. Our physicians not only provide state-of-the-art treatment for patients, but they also lead the field with primary immune deficiency research and new treatment trials.

We have many nurse practitioners dedicated to caring for patients with inborn errors of immunity. Patients in our practice also work with a dedicated nurse coordinator who helps patients navigate their medical care. Our practice is special because we provide cutting-edge diagnostics and treatments for our patients and also maintain a supportive and caring team-based environment.

Through my research, I want to improve allogeneic hematopoietic cell transplantation for patients with primary immunodeficiencies. I’m also working to improve the treatment of patients with X-linked inhibitor of apoptosis (XIAP) deficiency and hemophagocytic lymphohistiocytosis (HLH).

In my free time, I like to play the piano, bake and spend time with my family.

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information


Prospective two center study of CD38 bright CD8+ effector memory T-cells as a predictor of acute GVHD. Khandelwal, P; Chaturvedi, V; Owsley, E; Efebera, YA; Choe, H; Bostic, M; Kumchala, P; Rajgolikar, G; Ranganathan, P; Garzon, R; et al. Transplantation Reports. 2022; 7.

Quercetin ameliorates XIAP deficiency-associated hyperinflammation. Chiang, SC C; Owsley, E; Panchal, N; Chaturvedi, V; Terrell, CE; Jordan, MB; Mehta, PA; Davies, SM; Akeno, N; Booth, C; et al. Blood. 2022; 140:706-715.

Does shining a spotlight on XIAP deficiency bring the role of allogeneic HCT into better focus?. Marsh, RA. Journal of Allergy and Clinical Immunology. 2022; 150:297-298.

Multifocal Trichosporon asahii Infection in a Patient With Chronic Granulomatous Disease. Khalil, N; Kasten, JL; Marsh, RA; Danziger-Isakov, L. Journal of the Pediatric Infectious Diseases Society. 2022.

Reduced Intensity Conditioning Allogeneic Transplant for SCID Associated with Cartilage Hair Hypoplasia. Fitch, T; Bleesing, J; Marsh, RA; Chandra, S. Journal of Clinical Immunology. 2022.

Excessive IL-10 and IL-18 trigger hemophagocytic lymphohistiocytosis-like hyperinflammation and enhanced myelopoiesis. Tang, Y; Xu, Q; Luo, H; Yan, X; Wang, G; Hu, L; Jin, J; Witte, DP; Marsh, RA; Huang, L; et al. Journal of Allergy and Clinical Immunology. 2022.

Rheumatologic diseases in patients with inborn errors of immunity in the USIDNET registry. Padem, N; Wright, H; Fuleihan, R; Garabedian, E; Suez, D; Cunningham-Rundles, C; Marsh, RA; Khojah, A. Clinical Rheumatology. 2022; 41:2197-2203.

Granulocyte Transfusions in Patients with Chronic Granulomatous Disease Undergoing Hematopoietic Cell Transplantation or Gene Therapy. Arnold, DE; Chellapandian, D; Parikh, S; Mallhi, K; Marsh, RA; Heimall, JR; Grossman, D; Chitty-Lopez, M; Murguia-Favela, L; Gennery, AR; et al. Journal of Clinical Immunology. 2022; 42:1026-1035.

Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data From the USIDNET Registry. Durkee-Shock, J; Zhang, A; Liang, H; Wright, H; Magnusson, J; Garabedian, E; Marsh, RA; Sullivan, KE; Keller, MD; Puck, J; et al. Journal of Allergy and Clinical Immunology: In Practice. 2022; 10:1334-1341.e6.

Preemptive hematopoietic cell transplantation for asymptomatic patients with X-linked lymphoproliferative syndrome type 1. Tomomasa, D; Booth, C; Bleesing, JJ; Isoda, T; Kobayashi, C; Koike, K; Taketani, T; Sawada, A; Tamura, A; Marsh, RA; et al. Clinical Immunology. 2022; 237.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey